DEA Archives | Rhizo Sciences Hemp CBD, CBG and Medical Cannabis Flower Extraction

Pharma Grade CBD Products to be Rescheduled
Gallery
Pharma Grade CBD Products to be Rescheduled

Medical Cannabis

Pharma Grade CBD Products to be Rescheduled

By Dallas McMillan|2018-09-29T00:06:18+00:00Sep,18 29|Categories: Medical Cannabis|Tags: Cannabidiol, CBD, DEA, Epidiolex, Epilepsy, FDA, GMP, GW Pharma, pharma grade CBD|

Pharma Grade CBD Products to be Rescheduled to Schedule V Pharma Grade CBD Products such as Epidiolex will be Schedule V - comparable to codeine-containing cough syrups - indicating a low potential for abuse and effectiveness as a therapeutic drug. The Drug Enforcement Agency published a notification on the FDA CBD rescheduling in the Federal Register. "With [...]

CBD Isolate Drugs Rescheduled by the FDA
Gallery
CBD Isolate Drugs Rescheduled by the FDA

CBD

CBD Isolate Drugs Rescheduled by the FDA

By Dallas McMillan|2018-09-28T06:03:43+00:00Sep,18 28|Categories: CBD|Tags: Cannabidiol, Controlled Drug, DEA, DOJ, Epidiolex, FDA, GW Pharma, prescription medicines, Schedule I, Schedule V|

CBD Isolate Drugs Rescheduled by the FDA CBD isolate based drug Epidolex has been removed from Schedule I and placed in Schedule V which will make access to the drug much simpler for patients who can afford it. The rescheduling is a major breakthrough in the medical cannabis and hemp CBD industry because it finally recognises [...]